Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02202525

Enrollment

2148

Registered

2014-07-29

Start date

2001-01-31

Completion date

Unknown

Last updated

2014-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Interventions

DRUGMicardis®

DRUGOther hypertensives

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with essential arterial hypertension needing a new antihypertensive therapy * A patient was included by the physician only if he/she had agreed after being informed about the study

Design outcomes

Primary

Measure	Time frame
Changes from baseline in pulse pressure	Up to 3 months after start of treatment
Number of patients with adverse drug reactions	Up to 3 months after start of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026